Long-term safety and decrease of pill burden by tenapanor therapy: a phase 3 open-label study in hemodialysis patients with hyperphosphatemia

Phosphate binders (PBs) generally have a high pill burden. Tenapanor selectively inhibits sodium/hydrogen exchanger isoform 3, reducing intestinal phosphate absorption. Tenapanor is a novel drug administered as a small tablet, twice daily. This multicenter, open-label, single-arm, phase 3 study aime...

Descripción completa

Detalles Bibliográficos
Autores principales: Koiwa, Fumihiko, Sato, Yu, Ohara, Meiko, Nakanishi, Kaoru, Fukagawa, Masafumi, Akizawa, Tadao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10625594/
https://www.ncbi.nlm.nih.gov/pubmed/37925471
http://dx.doi.org/10.1038/s41598-023-45080-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10625594/
https://www.ncbi.nlm.nih.gov/pubmed/37925471
http://dx.doi.org/10.1038/s41598-023-45080-9

Ejemplares similares